Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 105

Sort by

Sort Order Select

Journal Articles

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

Blood (2023) 142 (Supplement 1): 6638.

https://doi.org/10.1182/blood-2023-183100

Published: 2023

Journal Articles

An Idiotype Vaccine Strategy Utilizing Targeted NGS and Cell Free Protein Synthesis System Ensures Identification and Production of Human Idiotype Antigens, and Shows Promising Results in Preclinical Models of B-Cell Lymphoma with a Novel TLR7/8 Agonist-Based Adjuvant and Anti-PD-L1 Antibody

Sungho Moon, Miyeon Chun, Sangwoo Kim, Hanna Seo, Kyeong eun Kim, Geummi Cho, Chul Kim, Dok Hyun Yoon, Yoon Se Lee, Tae Min Kim, Eun-Jae Chung, Junho Chung

Blood (2023) 142 (Supplement 1): 2811.

https://doi.org/10.1182/blood-2023-185255

Published: 2023

Journal Articles

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

Blood (2023) 142 (Supplement 1): 302.

https://doi.org/10.1182/blood-2023-179304

Published: 2023

Journal Articles

A Novel PI3K γ/δ and DNA-PK Triple Inhibitor, BR101801, for r/r PTCL: A Phase 1a/b, Multi-Center, Open-Label Clinical Trial

Bong-Seog Kim, Seok Jin Kim, Dok Hyun Yoon, Jin Seok Kim, Tae Min Kim, Eunyoung Lee, Jeong-Ok Lee, Deok-Hwan Yang, Won-Sik Lee

Blood (2023) 142 (Supplement 1): 1701.

https://doi.org/10.1182/blood-2023-173010

Published: 2023

Journal Articles

Double Step-up Dosing (2SUD) Regimen Mitigates Severe Icans and CRS While Maintaining High Efficacy in Subjects with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL) Treated with AZD0486, a Novel CD19xCD3 T-Cell Engager (TCE): Updated Safety and Efficacy Data from the Ongoing First-in-Human (FIH) Phase 1 Trial

Sameh Gaballa, Ranjit Nair, Ryan W Jacobs, Sumana Devata, Seok-Goo Cho, Don A. Stevens, Dok Hyun Yoon, Nirav N. Shah, Denise Brennan, Jason Law, Robert Chen, David Sermer, Robin Lesley, Ben Buelow, Alessandra Forcina, Jing-Zhou Hou

Blood (2023) 142 (Supplement 1): 1662.

https://doi.org/10.1182/blood-2023-174668

Published: 2023

Journal Articles

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

Blood (2023) 142 (Supplement 1): 6675.

https://doi.org/10.1182/blood-2023-174439

Published: 2023

Journal Articles

A First-in-Human Phase I Study of AT101, a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 in Adults with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Blood (2023) 142 (Supplement 1): 2096.

https://doi.org/10.1182/blood-2023-189369

Published: 2023

Journal Articles

Nivolumab in Relapsed or Refractory Primary CNS Lymphoma: Multicenter, Retrospective Study

Jun Ho Yi, Seok Jin Kim, Sang A Kim, Jongheon Jung, Dok Hyun Yoon

Blood (2023) 142 (Supplement 1): 1772.

https://doi.org/10.1182/blood-2023-186554

Published: 2023

Journal Articles

Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)

Blood (2023) 142 (Supplement 1): 305.

https://doi.org/10.1182/blood-2023-172962

Published: 2023

Journal Articles

Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic Agents Among Patients with B-Cell Non-Hodgkin Lymphoma in a Phase 1b/2, Multicenter, Open-Label Study: Assessing Safety, Tolerability, and Preliminary Efficacy (EPCORE NHL-5)

Laurie H. Sehn, Johannes Duell, Irit Avivi, Joshua Brody, Dok Hyun Yoon, Brian Elliot, Satya R. Siddani, Yang Bai, Apurvasena Parikh, Mostafa M. Seliem, Minh Dinh, Alan P. Skarbnik

Blood (2022) 140 (Supplement 1): 12108–12109.

https://doi.org/10.1182/blood-2022-157596

Published: 2022

Journal Articles

Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL

Jing-Zhou Hou, Ryan Jacobs, Seok-Goo Cho, Sumana Devata, Sameh Gaballa, Dok Hyun Yoon, Don A. Stevens, Jin Seok Kim, Ben Buelow, Ranjit Nair

Blood (2022) 140 (Supplement 1): 1474–1475.

https://doi.org/10.1182/blood-2022-166385

Published: 2022

Journal Articles

Impact of BCL2/MYC Protein Dual Expression and Other Clinical Factors on the Risk of Central Nervous System Progression in Patients with Primary Breast Diffuse Large B-Cell Lymphoma

Blood (2022) 140 (Supplement 1): 9498–9500.

https://doi.org/10.1182/blood-2022-165716

Published: 2022

Journal Articles

Prognostic Significance of Vitamin D Level in Patients with Multiple Myeloma

Sejin Kim, Hyungwoo Cho, Miyoung Kim, Yoon Seok Choi, Dok Hyun Yoon

Blood (2022) 140 (Supplement 1): 7154–7155.

https://doi.org/10.1182/blood-2022-166387

Published: 2022

Journal Articles

Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell Lymphoma

Yuqin Song, Won-Seog Kim, Dok-Hyun Yoon, Haiyan Yang, Junning Cao, Dongmei Ji, Youngil Koh, Hongmei Jing, Hyeon-Seok Eom, Jae-Yong Kwak, Won-Sik Lee, Jong-Seok Lee, Ho-Jin Shin, Jie Jin, Mei Wang, Jingrun Li, Jun Zhu

Blood (2022) 140 (Supplement 1): 6545–6546.

https://doi.org/10.1182/blood-2022-162947

Published: 2022

Journal Articles

Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation

Paolo Strati, Tae Min Kim, Alexey V Danilov, Chan Y. Cheah, Dok Hyun Yoon, Wojciech Jurczak, Shringi Sharma, Jeong Lim Yoon, Serena Arduini, Jamal Saeh, Richard F. Olsson, Gareth Gregory

Blood (2022) 140 (Supplement 1): 6656–6658.

https://doi.org/10.1182/blood-2022-165979

Published: 2022

Journal Articles

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Blood (2022) 140 (Supplement 1): 3753–3755.

https://doi.org/10.1182/blood-2022-157729

Published: 2022

Journal Articles

Safety and Effectiveness of Rituximab Biosimilar CT-P10 during Routine Clinical Practice: Final Analysis of a Post-Marketing Surveillance Study in the Republic of Korea

Seok-Goo Cho, Jae-Cheol Jo, Young-Woo Jeon, Dajung Kim, Deok-Hwan Yang, Won Sik Lee, Yoon Seok Choi, Jun Ho Yi, Dok Hyun Yoon, Jee Hyun Kong, Jung-yoon Choe, Sung Hyun Kim, Keum Young Ahn, TaeHong Park, Jeongah Park, Sangeun Han

Blood (2022) 140 (Supplement 1): 10960–10962.

https://doi.org/10.1182/blood-2022-156478

Published: 2022

Journal Articles

Prognostic Significance of Vitamin D Level at Diagnosis in Patients with Peripheral T-Cell Lymphoma

Young Gyu Park, Hyungwoo Cho, Jin Sook Ryu, Chan-Sik Park, Sang-wook Lee, Yoon Sei Lee, Yoon Seok Choi, Dok Hyun Yoon

Blood (2022) 140 (Supplement 1): 9441–9442.

https://doi.org/10.1182/blood-2022-158952

Published: 2022

Journal Articles

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Yuqin Song, Ning Ding, Dok Hyun Yoon, John C. Reneau, Ryan A. Wilcox, Won Seog Kim, Youn H. Kim, Michael S. Khodadoust, Tatyana A. Feldman, Costas K. Yannakou, Pratyush Giri, Jonathan E Brammer, Lih-Yun Hsu, Hongwei Yuan, Erik Verner, Suresh Mahabhashyam, Richard A. Miller

Blood (2022) 140 (Supplement 1): 8857–8859.

https://doi.org/10.1182/blood-2022-159177

Published: 2022

Journal Articles

Clinical Significance of Epstein-Barr Virus in Peripheral T-Cell Lymphoma, Not Otherwise Specified

So Heun Lee, Hyungwoo Cho, Jin Sook Ryu, Chan-Sik Park, Sang-wook Lee, Yoon Sei Lee, Yoon Seok Choi, Dok Hyun Yoon

Blood (2022) 140 (Supplement 1): 3709–3710.

https://doi.org/10.1182/blood-2022-165020

Published: 2022

NARROW

Treatment Patterns in Patients with Mantle Cell Lymphoma: Updated Report of the Asia-Pacific Multinational Retrospective Registry Study

An Idiotype Vaccine Strategy Utilizing Targeted NGS and Cell Free Protein Synthesis System Ensures Identification and Production of Human Idiotype Antigens, and Shows Promising Results in Preclinical Models of B-Cell Lymphoma with a Novel TLR7/8 Agonist-Based Adjuvant and Anti-PD-L1 Antibody

Efficacy and Safety of Valemetostat Monotherapy in Patients with Relapsed or Refractory Peripheral T-Cell Lymphomas: Primary Results of the Phase 2 VALENTINE-PTCL01 Study

A Novel PI3K γ/δ and DNA-PK Triple Inhibitor, BR101801, for r/r PTCL: A Phase 1a/b, Multi-Center, Open-Label Clinical Trial

Cardiovascular Toxicity after Carfilzomib, Lenalidomide, and Dexamethasone Combination Chemotherapy in the Real-World 364 Asian Multiple Myeloma Patients on Behalf of the Korean Multiple Myeloma Working Party (KMM2201 study)

A First-in-Human Phase I Study of AT101, a Novel Anti-CD19 Chimeric Antigen Receptor T Cell Product Targeting a Membrane-Proximal Domain of CD19 in Adults with Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

Nivolumab in Relapsed or Refractory Primary CNS Lymphoma: Multicenter, Retrospective Study

Golidocitinib in Treating Refractory or Relapsed Peripheral T- Cell Lymphoma: Full Analysis of the Multinational Pivotal Study Results (JACKPOT8)

Subcutaneous Epcoritamab in Novel Combinations with Antineoplastic Agents Among Patients with B-Cell Non-Hodgkin Lymphoma in a Phase 1b/2, Multicenter, Open-Label Study: Assessing Safety, Tolerability, and Preliminary Efficacy (EPCORE NHL-5)

Interim Results of the Phase 1 Study of Tnb-486, a Novel CD19xCD3 T-Cell Engager, in Patients with Relapsed/Refractory (R/R) B-NHL

Impact of BCL2/MYC Protein Dual Expression and Other Clinical Factors on the Risk of Central Nervous System Progression in Patients with Primary Breast Diffuse Large B-Cell Lymphoma

Prognostic Significance of Vitamin D Level in Patients with Multiple Myeloma

Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell Lymphoma

Phase 1b/2a Study of AZD4573 (CDK9i) and Acalabrutinib in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Results from Dose-Escalation

Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Safety and Effectiveness of Rituximab Biosimilar CT-P10 during Routine Clinical Practice: Final Analysis of a Post-Marketing Surveillance Study in the Republic of Korea

Prognostic Significance of Vitamin D Level at Diagnosis in Patients with Peripheral T-Cell Lymphoma

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Clinical Significance of Epstein-Barr Virus in Peripheral T-Cell Lymphoma, Not Otherwise Specified

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only